30. November 2016

Press Release: Zedira receives funding by the German Government for the development of transglutaminase inhibitors for the treatment of diabetic nephropathy



Darmstadt, November, 30th 2016  

Zedira announced today that the BMBF will grant additional 1.5 million Euros funding to the company within the highly competitive SME-Innovative program over the next three years.
The aim of the project is for Zedira to develop small molecule tissue transglutaminase inhibitors that are orally bioavailable. Transglutaminase is considered to be a scientifically validated target in certain fibrotic diseases such as diabetic nephropathy. Kidney injury is one of the most severe complications of diabetes.

The funding will allow Zedira to expand its leadership in low-molecular-weight transglutaminase blockers. In fact, Zedira’s ZED1227 is the first transglutaminase blocker ever to be evaluated in clinical trials for celiac disease, and is currently in phase 1b trials.  Additionally, the core biotech company has recently developed ZED3197, the first drug candidate to target blood coagulation factor XIII (F13, plasma transglutaminase). This compound (a peptidomimetic) has proved to be a potent anticoagulant without prolonging the bleeding time in an animal model of venous stasis and reperfusion.

About Zedira:
The Darmstadt-based biotech company has a focus on transglutaminase-linked conditions in the arena of autoimmunity, fibrotic disease and thrombosis. The company develops, produces and markets specialized reagents and kits for research and development as well as for clinical diagnostics. Zedira is a portfolio company of the German High-Tech Gründerfonds.

Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • Life Sciences 2019: Post-translational modifications and cell signalling

    17.03.2019 - 18.03.2019
    Nottingham, UK

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France